Biote Corp. Form 8-K Summary
Business context and reporting period
Biote Corp. filed a Form 8-K regarding corporate governance matters. The earliest reported event occurred on November 3, 2022; the report was signed and filed on November 7, 2022. Biote’s Class A common stock and warrants trade on Nasdaq under BTMD and BTMDW, respectively.
Board appointment and compensation
- The board increased from six to seven directors and appointed Debra L. Morris as an independent Class II director, effective immediately.
- Ms. Morris was also appointed to the Audit Committee. Her term expires at the 2023 annual meeting of stockholders.
- Ms. Morris recently served as executive vice president and chief financial officer of Apria, Inc. and has prior public-company board and audit committee experience.
- Her compensation includes a $45,000 annual board retainer, a $10,000 annual Audit Committee retainer, and an initial option award with a grant-date fair value of $350,000, vesting in 36 substantially equal monthly installments.
- She is eligible for annual equity awards with a grant-date fair value of up to $175,000, subject to applicable proration and vesting conditions.
- Outstanding equity awards granted under the non-employee director policy would fully vest upon a change in control, subject to the stated conditions.
- The company entered into its standard indemnification agreement with Ms. Morris.
Financial metrics and material changes
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating or financial metrics. It also does not report a material change in financial results versus a comparable prior period.
Outlook, risks, contingencies, and unusual items
The filing contains no updated business outlook or financial guidance. The principal disclosed items are the addition of an independent director, Audit Committee membership, related equity compensation, and indemnification arrangements. The Item 7.01 press release was furnished rather than filed and is not incorporated by reference into the company’s Exchange Act filings.
Investor verification checklist
- Verify the grant-date fair value, option exercise price, share count, and vesting terms of Ms. Morris’s initial equity award.
- Review the November 7, 2022 press release filed as Exhibit 99.1 for any additional commentary.
- Confirm the board’s post-appointment committee composition and compliance with Nasdaq independence requirements.
- Review subsequent filings for changes to director compensation, board membership, or the effects of the appointment on governance and oversight.